



## Clinical trial results:

**A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY TO DEMONSTRATE THE EFFICACY AND ASSESS THE SAFETY OF CD07805/47 GEL 0.5% APPLIED TOPICALLY ONCE DAILY IN SUBJECTS WITH MODERATE TO SEVERE FACIAL ERYTHEMA OF ROSACEA**

### Summary

EudraCT number	2012-001044-22
Trial protocol	SE
Global end of trial date	18 October 2013

### Results information

Result version number	v1 (current)
This version publication date	04 February 2016
First version publication date	04 February 2016

### Trial information

#### Trial identification

Sponsor protocol code	RD.03.SPR.40174
-----------------------	-----------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01789775
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Galderma R&D SNC
Sponsor organisation address	Les Templiers, 2400 Route des Colles, Biot, France,
Public contact	CTA Coordinator, Galderma R&D SNC, +33 (0)493-95-70-85 , cta.coordinator@galderma.com
Scientific contact	CTA Coordinator, Galderma R&D SNC, +33 (0)493-95-70-85 , cta.coordinator@galderma.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	19 March 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	18 October 2013
Global end of trial reached?	Yes
Global end of trial date	18 October 2013
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To demonstrate efficacy and to assess the safety of CD07805/47 gel 0.5%, applied topically once daily for 29 days versus vehicle control, in subjects with moderate to severe facial erythema of rosacea.

Protection of trial subjects:

All study participants were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	24 September 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Sweden: 6
Country: Number of subjects enrolled	Russian Federation: 92
Country: Number of subjects enrolled	France: 14
Worldwide total number of subjects	112
EEA total number of subjects	20

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	107
From 65 to 84 years	5
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Participants took part in the study at 8 investigational centers located in France, Russia, and Sweden. from 28 Dec 2012 to 18 Oct 2013.

### Pre-assignment

Screening details:

A total of 130 subjects were screened and 112 subjects were randomized in a 1:1 ratio to receive either CD07805/47 Gel 0.5% or Vehicle Gel for once daily application.

### Period 1

Period 1 title	Treatment period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	CD07805/47 0.5% Gel

Arm description:

Subject who received Brimonidine (CD07805/47), gel cutaneous use, once application on the face for a period of 29 days

Arm type	Experimental
Investigational medicinal product name	Brimonidine tartrate
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Gel
Routes of administration	Cutaneous use

Dosage and administration details:

0.5%

<b>Arm title</b>	Placebo Gel
------------------	-------------

Arm description:

Subject who received Matching Placebo gel, gel cutaneous use, once application on the face for a period of 29 days

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Gel
Routes of administration	Cutaneous use

Dosage and administration details:

0%

<b>Number of subjects in period 1</b>	CD07805/47 0.5% Gel	Placebo Gel
Started	57	55
Completed	50	53
Not completed	7	2
Adverse event, non-fatal	6	1
Protocol deviation	1	1

## Baseline characteristics

### Reporting groups

Reporting group title	CD07805/47 0.5% Gel
-----------------------	---------------------

Reporting group description:

Subject who received Brimonidine (CD07805/47), gel cutaneous use, once application on the face for a period of 29 days

Reporting group title	Placebo Gel
-----------------------	-------------

Reporting group description:

Subject who received Matching Placebo gel, gel cutaneous use, once application on the face for a period of 29 days

Reporting group values	CD07805/47 0.5% Gel	Placebo Gel	Total
Number of subjects	57	55	112
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	56	51	107
From 65-84 years	1	4	5
85 years and over	0	0	0
Age continuous Units: years			
arithmetic mean	43.2	44.9	
standard deviation	± 10.8	± 12.1	-
Gender categorical Units: Subjects			
Female	41	40	81
Male	16	15	31

## End points

### End points reporting groups

Reporting group title	CD07805/47 0.5% Gel
Reporting group description:	
Subject who received Brimonidine (CD07805/47), gel cutaneous use, once application on the face for a period of 29 days	
Reporting group title	Placebo Gel
Reporting group description:	
Subject who received Matching Placebo gel, gel cutaneous use, once application on the face for a period of 29 days	

### Primary: Clinician Erythema Assessment (CEA) and Patient Self Assessment(PSA).

End point title	Clinician Erythema Assessment (CEA) and Patient Self Assessment(PSA).
End point description:	
Composite Success is defined as 1-grade improvement on both Clinician Erythema Assessment (CEA) and Patient Self Assessment(PSA).	
End point type	Primary
End point timeframe:	
Day 29 at Hours 3, 5, 7, and 9	

End point values	CD07805/47 0.5% Gel	Placebo Gel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	57	55		
Units: Participants				
Hour 3	48	32		
Hour 5	46	33		
Hour 7	43	35		
Hour 9	39	33		

### Statistical analyses

Statistical analysis title	Statistical analysis on primary endpoint
Comparison groups	CD07805/47 0.5% Gel v Placebo Gel
Number of subjects included in analysis	112
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0483
Method	Generalized Estimating Equation (GEE)

---

**Secondary: Clinician Erythema Assessment (CEA) and Patient Self Assessment(PSA).**

---

End point title	Clinician Erythema Assessment (CEA) and Patient Self Assessment(PSA).
-----------------	---

End point description:

Composite Success is defined as 1-grade improvement on both Clinician Erythema Assessment (CEA) and Patient Self Assessment(PSA).

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 - 30 minutes after application

---

<b>End point values</b>	CD07805/47 0.5% Gel	Placebo Gel		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	57	55		
Units: participants	27	7		

**Statistical analyses**

<b>Statistical analysis title</b>	Statistical analysis on secondary endpoint
Comparison groups	CD07805/47 0.5% Gel v Placebo Gel
Number of subjects included in analysis	112
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mantel-Haenszel

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

The collection of AEs is from the time that a subject signs the ICF to their final visit.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	15.0
--------------------	------

### Reporting groups

Reporting group title	CD07805/47 0.5% Gel
-----------------------	---------------------

Reporting group description:

Subject who received Brimonidine (CD7805/47), 0.5% gel cutaneous use,

Reporting group title	Placebo gel
-----------------------	-------------

Reporting group description: -

Serious adverse events	CD07805/47 0.5% Gel	Placebo gel	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 57 (1.75%)	0 / 55 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Skin and subcutaneous tissue disorders			
Angioedema/urticaria			
subjects affected / exposed	1 / 57 (1.75%)	0 / 55 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	CD07805/47 0.5% Gel	Placebo gel	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	16 / 57 (28.07%)	3 / 55 (5.45%)	
Skin and subcutaneous tissue disorders			
Dermatitis allergic			
subjects affected / exposed	2 / 57 (3.51%)	1 / 55 (1.82%)	
occurrences (all)	2	1	
Erythema			

subjects affected / exposed	3 / 57 (5.26%)	0 / 55 (0.00%)	
occurrences (all)	3	0	
Pruritus			
subjects affected / exposed	2 / 57 (3.51%)	0 / 55 (0.00%)	
occurrences (all)	0	0	
Rosacea			
subjects affected / exposed	7 / 57 (12.28%)	1 / 55 (1.82%)	
occurrences (all)	7	1	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 July 2013	specific protocol amendment for France : inclusion criteria n°5 (Female of childbearing potential). Updates according to local requirement: addition of an exclusion criteria (n°18) for adults protected by the law); process for reporting of SUSAR in France was further elaborate; exclusion of French sites for facial photographs

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

not applicable
----------------

Notes: